MBL International offers a wide variety of products to help in the research of IL-18.
IL-18 Therapies Targeting Inflammatory Disease
CD1d Tetramers for Monitoring Invariant Natural Killer T (iNKT) cells
MBL International offers CD1d tetramers prepared by tetramerisation of complexes of CD1d and β2m by PE- or APC- labelled streptavidin.
Conquering the abyss: scaling biomanufacturing without the tank
Future Fields is focussed on scaling biomanufacturing.
World First: Human Growth Factor Made From Fruit Flies for Life Science Applications Shows High Performance
Future Fields is pleased to announce the performance results of their first human growth factor, Recombinant Human FGF2.
New B7 Family Immune Checkpoint Proteins
Recently 5 new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 & B7-H7, were identified, all of them possibly of high interest in immunotherapy research.
HVEM – BTLA – LIGHT – CD160 Network
The checkpoint receptors/ligands system HVEM, LIGHT, CD160 and BTLA (CD272) is part of a complex network of overlapping receptor interactions.
TIGIT – CD155 – CD112 – CD226 Network
Tumour cells exploit the dominance of the inhibitory TIGIT pathway to avoid immune-mediated destruction.
LAG-3 – Major Histocompatibility Complex (MHC) – T Cell Receptor (TCR) Pathway
Dual inhibition of LAG-3 and other checkpoint pathways may synergistically increase T cell antitumour activity.
CTLA-4 [CD152] – CD80 – CD86 – CD28 Network
![CTLA-4 [CD152] – CD80 – CD86 – CD28 Network](https://www.caltagmedsystems.co.uk/information/wp-content/uploads/cd28-600x300.png "CTLA-4 [CD152] – CD80 – CD86 – CD28 Network")
Targeting CTLA-4 restores immune response by more accumulation, function & survival of T cells, depletion of Tregs & better antitumour response.
CD40 – CD40L Pathway
CD40 is a member of the TNF receptor family expressed by APCs and B cells whereas its ligand, CD40L (CD154), is expressed by activated T cells.